Aster DM Healthcare Limited has announced a shareholder meeting scheduled for March 10, 2026, to approve its proposed scheme of amalgamation with Quality Care India Limited. The meeting represents a crucial step in what the company describes as the largest transaction in India's hospital sector, with strong shareholder support backing the strategic merger.

Meeting Details and Voting Process

The equity shareholders meeting will be conducted through video conferencing and other audio-visual means, providing accessibility for all stakeholders.

Strategic Merger Overview

The proposed amalgamation aims to create one of India's top 3 hospital chains, with the company highlighting strong shareholder support. The merger has already received approval from an overwhelming majority of 99.998% of shareholders for the share swap arrangement preceding the merger.

The combined entity is positioned to establish a comprehensive healthcare platform with significant operational scale:

Financial and Operational Benefits

The merger is expected to deliver substantial synergies and operational improvements. The company has identified synergies with an EBITDA upside potential of 10-15%, computed as a percentage of pro-forma EBITDA of the merged entity.

Key strategic advantages include stronger financial, operational and return metrics, significant opportunities for both brownfield and greenfield expansion, multiple synergies to accelerate growth and improve margins, and enhanced clinical excellence capabilities.

Governance Framework

The company has addressed stakeholder concerns regarding governance through a comprehensive framework. Both Aster Promoters and Blackstone have committed to specific governance measures, including waiving director nomination rights when their shareholding falls to 10%. The governance structure includes board committee composition determined in accordance with applicable law, mandatory independent director representation on all committees, and robust check-and-balance mechanisms for committee decisions.

Regulatory Compliance

The meeting notice has been issued under Regulation 30 and other applicable provisions of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The scheme of amalgamation is being pursued under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The company emphasizes that the proposed merger aligns with long-term shareholder interests, combining a strong business case with reasonable valuation and governance rights designed to ensure continued stakeholder alignment.

Aster DM Healthcare Limited has entered into a comprehensive Shareholders' Agreement (SHA) with its wholly owned subsidiary, Aster DM Super-specialty Hospital (Sarjapur) Private Limited, in connection with the planned issuance of Compulsorily Convertible Preference Shares (CCPS). The agreement was executed on February 26, 2026, as disclosed under Regulation 30 of SEBI Listing Regulations.

Shareholders' Agreement Details

The SHA establishes governance frameworks and operational protocols for the Sarjapur Entity's fundraising initiative from potential investors. The agreement records governance-related matters including board and shareholders' meetings, share transfer restrictions, and call option provisions in favor of the parent company.

Key Provisions and Rights

The shareholders' agreement provides Aster DM Healthcare with significant control mechanisms over its subsidiary's operations and shareholding structure. The company retains the right to nominate directors on the Sarjapur Entity's board, ensuring continued oversight of strategic decisions.

Strategic Fundraising Initiative

The Sarjapur Entity intends to raise funds from potential investors through the CCPS mechanism, representing a strategic approach to capital mobilization while maintaining parent company control. This structure allows external investment while preserving Aster DM Healthcare's governance rights and operational oversight.

The transaction is conducted on an arm's length basis and does not constitute a related party transaction under SEBI Listing Regulations, as no transfer of resources, services, or obligations occurs between the company and its subsidiary. The agreement ensures that Aster DM Healthcare maintains its promoter status and strategic control over the subsidiary's future direction.